Indivior Pharmaceuticals (INDV) EPS (Weighted Average and Diluted) (2024 - 2025)
Historic EPS (Weighted Average and Diluted) for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q3 2025 value amounting to $0.33.
- Indivior Pharmaceuticals' EPS (Weighted Average and Diluted) rose 10625.0% to $0.33 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.01, marking a year-over-year increase of 15062.96%. This contributed to the annual value of $0.05 for FY2024, which is 10543.48% up from last year.
- Indivior Pharmaceuticals' EPS (Weighted Average and Diluted) amounted to $0.33 in Q3 2025, which was up 10625.0% from $0.14 recorded in Q2 2025.
- In the past 5 years, Indivior Pharmaceuticals' EPS (Weighted Average and Diluted) registered a high of $232.3 million during Q1 2023, and its lowest value of -$231.6 million during Q3 2023.
- Over the past 4 years, Indivior Pharmaceuticals' median EPS (Weighted Average and Diluted) value was $0.36 (recorded in 2025), while the average stood at $27.8 million.
- Over the last 5 years, Indivior Pharmaceuticals' EPS (Weighted Average and Diluted) had its largest YoY gain of 12097.04% in 2023, and its largest YoY loss of 40769.11% in 2023.
- Indivior Pharmaceuticals' EPS (Weighted Average and Diluted) (Quarter) stood at -$2.37 in 2022, then soared by 120.97% to $0.5 in 2023, then plummeted by 67.76% to $0.16 in 2024, then surged by 106.25% to $0.33 in 2025.
- Its last three reported values are $0.33 in Q3 2025, $0.14 for Q2 2025, and $0.38 during Q1 2025.